Best European Hematology Association Podcasts (2024)

1
What’s so Great About the P-value? A Statistician’s Point of View 30:24

5M ago30:24

30:24

Dr Stephen Hibbs invites HemaSphere Associate Editor Prof Robert K Hills to discuss statistics in scientific writing in an entertaining and informative episode: What’s so Great About the P-value? A Statistician’s Point of View. This discussion covers the overlap of statistics and hematology with themes like the importance of P value and the use of …

1
This Is Going to Hurt: Revisiting the Patient Experience of Bone Marrow Biopsies 24:16

6M ago24:16

24:16

Dr Stephen Hibbs invites Dr Joseph Taylor to a discussion based on Dr Hibbs popular HemaTopics article, This Is Going to Hurt: Revisiting the Patient Experience of Bone Marrow Biopsies. The conversation ranges from the type of training providers receive, how to talk to patients about these bone marrow biopsies, and some of the outstanding questions…

1
The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children 27:29

7M ago27:29

27:29

Though many advances have been made in neutropenias, diagnosis and management are still based on physicians’ experience or local practices. Prof Francesca Fioredda and Prof Helen Papadaki, two co-authors of the HemaSphere published article The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children: A Consensus Between…

1
Part 1 - Comprehensive Diagnosis and Management of POEMS Syndrome 23:23

8M ago23:23

23:23

POEMS syndrome (Polyneuropathy Organomegaly, Endocrinopathy, M-protein and Skin changes) is rare, and systemic manifestations are commonly overlooked initially. Diagnosis is often delayed 12-16 months, during which patients can be severely disabled. No established treatment guidelines exist for POEMS. A recent HemaSphere published article, Comprehe…

1
Part 2 - Comprehensive Diagnosis and Management of POEMS Syndrome 24:32

8M ago24:32

24:32

POEMS syndrome (Polyneuropathy, Organomegaly, Endocrinopathy, M-protein and Skin changes) is rare, and systemic manifestations are commonly overlooked initially. Diagnosis is often delayed 12-16 months, during which patients can be severely disabled. No established treatment guidelines exist for POEMS. A recent HemaSphere published article Comprehe…

1
Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis 34:01

9M ago34:01

34:01

Machine Learning is a subsection in the field of Artificial Intelligence. How can this be used as a tool in hematology-oncology for advanced disease prognostification and beyond? Adrián Mosquera-Orgueira and Juan Carlos Hernández-Boluda, two co-authors of the HemaSphere published article Machine Learning Improves Risk Stratification in Myelofibrosi…

1
EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer 24:32

10M ago24:32

24:32

As the overall cancer death rate has declined over past decades and cancer survival has increased, unforeseen challenges are emerging. Thrombocytopenia, often associated with cancer disease or anticancer therapy, will be more present in thrombotic cancer patients, but evidence on how to treat these patients is lacking. Prof Anna Falanga discusses t…

1
“Long COVID-19” of Researchers: What to Do Next? 20:07

11M ago20:07

20:07

What to do next for “Long COVID-19” of researchers? A survey from scientists to scientists led by the Young European Hematology Association (Young EHA)committee led to this discussion about how COVID-19 impacted researchers, especially earlier in their career and without a network. What tools did they discover to get through it? Find it on the Hema…

1
Straight Talk with Dr. Brian J. Bolwell: Values 13:25

3+ y ago13:25

13:25

Welcome to the Oncology Times Podcast. Today on the Pod - Why do relatively few leaders live good values consistently? Why are so many people, especially in academic medicine, consumed with values that are emotion-based? We will discuss these ideas and more with Dr. Brian J. Bolwell, the Chairman of the Taussig Cancer Institute and Professor of Med…

1
Straight Talk with Dr. Brian J. Bolwell: Moments 15:07

3+ y ago15:07

15:07

In his recurring Oncology Times column “Straight Talk: Today's Cancer Centers,” Brian J. Bolwell, MD dispenses wisdom on how to be a better leader. In this episode, Dr. Bolwell revisits his column “Moments,” and discusses how to foster vulnerability, create psychological safety on a team, and embrace joy.…

1
September 2010 14:11

13+ y ago14:11

14:11

1
Multiple Myeloma: Big Survival Gains from Novel Agents 'in the Real World' 3:51

13+ y ago3:51

3:51

Evangelos Terpos, speaking at the European Hematology Association 2010 Congress in Barcelona, discusses his group's encouraging findings based on 10 years of experience with thalidomide, lenalidomide, and bortezomib.

1
From the European Hematology Association 2010 Congress: For Patients with Follicular Lymphoma, Rituximab Maintenance Therapy Cuts Risk of Recurrence in Half (Phase III PRIMA Study) 8:12

14y ago8:12

8:12

Speaking at the meeting in Barcelona, Gilles Salles of the University of Lyon discusses the results showing that patients who had achieved remissions after immunochemotherapy had only half the risk of recurrence if they also received rituximab maintenance therapy for two years compared with patients who did not.…

1
OT Clinical Advisory Editor for Hematology/Oncology Mikkael Sekeres, MD, MS 12:18

14y ago12:18

12:18

Dr. Sekeres, Director of the Leukemia Program at the Cleveland Clinic Taussig Cancer Institute and Chair of the Hematology/Oncology Pharmacy & Therapeutics Committee, discusses his particular research interests of myelodysplastic syndromes and acute myelogenous leukemia, including the overlaps between the two in older adults, new opportunities to b…

1
OT Clinical Advisory Editor for Oncology Ramaswamy Govindan, MD 8:39

14y ago8:39

8:39

Dr. Govindan, Professor of Medicine and Director of the Thoracic Medical Oncology Program at Washington University Alvin J. Siteman Cancer Center, elaborates on his article in the April 10 issue about the promise and excitement of the new advances in technology that are now making possible a “panoramic view of the rugged genomic landscape of the ca…

1
Treatment Recommendations for High- & Low-Risk Early Breast Cancer: New Data from EBCC 7, the European Breast Cancer Conference 9:40

14y ago9:40

9:40

Lori Pierce on breast-conserving therapy + adjuvant chemotherapy for BRCA 1 & 2 carriers; Annette Heemskerk-Gerritsen on the relationship between contralateral mastectomy & survival; and a recommendation by Ajay Sahu for a "cooling off" period for low-risk patients thinking of having prophylactic contralateral mastectomy.…

1
Pregnancy & Breast Cancer: New Updates from EBCC 7, the European Breast Cancer Conference 16:07

14y ago16:07

16:07

Oncology Times Hatem Azim on how pregnancy after breast cancer is safe and possibly protective; Angela Ives on why recent -- but not current -- pregnancy worsens breast cancer prognosis; and Sibylle Loibl on how chemotherapy is not generally hazardous to the fetus. Martine Piccart adds commentary & perspective…

1
Longer Follow-up Reveals: Aspirin Prevents Cancer in Lynch Syndrome 7:19

14+ y ago7:19

7:19

John Burn talking at ECCO15-ESMO34 in Berlin about his international study showing that aspirin prevented the development of Hereditary Non-Polyposis Colon Cancer in people genetically at risk for the disease.

1
The Disappointment of the NSABP C-08 Trial 9:05

14+ y ago9:05

9:05

Norman Wolmark on the study's frustrating but unequivocal results showing that bevacizumab did not extend disease-free survival in adjuvant therapy for early colon cancer at 3 years, even though there had been a benefit at 1 year. Also weighing in: Nicholas Petrelli

1
Aromatase Inhibitor Better than Tamoxifen for Initial Adjuvant Therapy for HR- Positive Breast Cancer, But Compliance an Issue! 6:57

14+ y ago6:57

6:57

Cornelis van de Velde at ECCO15-ESMO34 on the largest comparison of an aromatase inhibitor with tamoxifen as initial adjuvant therapy for patients with hormone receptor-positive breast cancer--analysis of results from the TEAM (Tamoxifen Exemestane Adjuvant Multinational) study reported at ECCO15-ESMO34.…

1
Research Policy Expert: Overhaul Cancer Research Priorities Globally Now! 9:39

14+ y ago9:39

9:39

Richard Sullivan at ECCO15-ESMO34 on the need for research that is more “trans-national” and funded globally to shift priorities to prevention, surgical innovation and technological development, and creative, “outward branching” thinking. The need, he says, is not just for more investment but for a radical change in thinking and culture.…

1
Swedish Registry Study Shows Hormone Therapy for Prostate Cancer Increased All Cardiovascular Mortality 4:20

14+ y ago4:20

4:20

Mieke Van Hemelrijck at ECCO15-ESMO34 on findings that cardiovascular mortality from heart failure and arrhythmia in addition to ischemic heart disease and myocardial infarction increased among patients treated with endocrine therapy—of whatever type—for their prostate cancer.

1
Advanced Biliary Cancer Controlled with Cetuximab Added to GEMOX 2:19

14+ y ago2:19

2:19

Éveline Boucher of Centre Eugene Marquis in France on the encouraging preliminary results of her Phase II open-label study of 101 patients reported at the ESMO World Congress on Gastrointestinal Cancer

1
Metastatic Colorectal Cancer: Capecitabine Equivalent to 5-FU in Irinotecan/Bevacizumab Combos 6:24

14+ y ago6:24

6:24

Michel Ducreux, Head of the GI Service at Institut Gustave Roussy, talks about the new evidence and its clinical implications, as reported in his Phase II study at the ESMO World Congress on Gastrointestinal Cancer.

1
Stage IV Pancreatic Islet Cell Tumors: Sunitinib Doubles Progression-Free Survival in Phase III Study 4:37

14+ y ago4:37

4:37

Eric Raymond of Beaujon University Hospital in France discusses his study reported at the ESMO World Congress on Gastrointestinal Cancer

1
KRAS-Driven Selection of Molecular Therapy for Metastatic Colorectal Cancer: Choosing Between Bevacizumab, Cetuximab, Panitumomab, or a Combination 3:39

14+ y ago3:39

3:39

Interviewed at the Palm Beach Cancer Symposium, John Macdonald, Chief Medical Officer of Aptium Oncology in Los Angeles, talks about his latest data on the relevance of KRAS tumor status—i.e., whether the gene is wild-type or mutant determines the sensitivity of the tumor to anti-EGF or anti-VEGF receptor therapy. He also discusses the disappointin…

1
CML: Hagop Kantarjian on Treating Patients with the T315I Mutation 9:09

14+ y ago9:09

9:09

Also: (1) Feasibility of patients becoming pregnant while having TKI treatment after having stable disease for at least two years; and (2) Decreased need for allogeneic transplant.

1
Oropharyngeal Cancer: Better Outlook with HPV-Directed Therapies 6:40

15y ago6:40

6:40

Marshall Posner, MD, talking from Palm Beach Cancer Symposium: Increased prevalence of HPV-related oropharyngeal cancers, more responsive to treatment with induction docetaxel, cisplatin, & 5-FU prior to standard chemoradiotherapy.

1
Breast Cancer: St. Gallen Meeting Endorses Multi-Gene Assays for Refining Chemo Decision 7:15

15y ago7:15

7:15

Also from the Palm Beach Cancer Symposium, Kathy Albain, MD, talks about the St. Gallen consensus meeting’s updated recommendations about adjuvant therapy for breast cancer—i.e., endorsing the 21-gene recurrence score and 70-gene profiling assay as key tools in decision-making for chemotherapy for ER-positive disease.…

1
The Smartest Oncologist in the World? – Well, at least in the US! 6:12

15y ago6:12

6:12

Stanley H. Winokur, MD, on his clever, fun, and ever-evolving one-minute daily Internet quiz that lets oncologists test their knowledge & compete against others. TheSmartestOncologist.com

1
Cancer-Related Fatigue 12:09

15y ago12:09

12:09

Paddy Stone of St. George's Hospital, University of London, & David Cella from Northwestern University Feinberg School of Medicine about the effective use of questionnaires for assessing, screening, and perhaps diagnosing cancer-related fatigue syndrome.

1
Bilateral Prophylactic Mastectomy for DCIS 10:46

15y ago10:46

10:46

Todd Tuttle from University of Minnesota & Abram Recht from Beth Israel Deaconess Medical Center on the surprisingly big recent increase in the use of prophylactic bilateral mastectomy for DCIS.

1
10th European Congress on Perspectives in Lung Cancer, Brussels 7:43

15y ago7:43

7:43

Silvia Novello and Giorgio Scagliotti on harnessing insulin-like growth factor receptor inhibition in a Phase II study that showed clinical activity of figitumumab to be at least as good as that of inhibitors of other growth factors already being used in cancer.

1
More from the ASH Annual Meeting! 31:26

15+ y ago31:26

31:26

Greater Role for Umbilical Cord Blood in Adult Transplants (Mary Eapen, commentary from Armand Keating). Ex Vivo Expansion of Cord Blood Derived Progenitor Cells: Patient Transplant Data (Colleen Delaney, commentary from Armand Keating). Erythropoiesis-Stimulating Agents in Cancer Patients: Meta-Analysis Mortality Findings (Julia Bohlius, commentar…

1
ASH Annual Meeting 26:58

15+ y ago26:58

26:58

Peter Goodwin talks to key investigators Francesco Zaja (on rituximab for ITP); Hannes Wandt (on how platelet transfusions may be able to be withheld in certain patients receiving stem cell transplants for hematologic cancers); and Michael Hallek and Tadeusz Robak (on improved benefits for CLL patients with rituximab added to standard chemotherapy)…

1
NCRI Conference, ASCO Annual Meeting, and Perspectives in Lung Cancer European Congress 20:17

15+ y ago20:17

20:17

New research for advanced NSCLC showing that combining monoclonal antibodies and chemotherapy can extend life: OTBN Editor Peter Goodwin and Producer Sarah Maxwell talk to Robert Pirker, Christian Manegold, Giorgio Scagliotti, Nick Thatcher, and Howard Sandler, MD. PLUS: Michel Coleman on the latest findings from the CONCORD study of international …

Podcasts Worth a Listen

European Hematology Association Podcasts

Podcasts Worth a Listen

Quick Reference Guide